DEFA14A: Enhabit to Go Private in Kinderhook Industries Acquisition

Enhabit, Inc. announces its acquisition by private equity firm Kinderhook Industries for $13.80 per share in cash.

Summary

• Enhabit, Inc. has entered into an agreement to be acquired by Kinderhook Industries, a leading middle-market private equity firm.
• Stockholders will receive $13.80 in cash for each vested share of Enhabit stock and for each outstanding unvested share from prior equity grants upon closing of the transaction.
• The transaction is expected to close in the second quarter of 2026, subject to stockholder and regulatory approvals.
• Day-to-day operations, team structures, strategy, and mission are expected to remain unchanged under Kinderhook's ownership.
• The company anticipates benefiting from additional resources and expertise to invest for the long term in its workforce, clinical capabilities, and supporting tools.
• Enhabit will continue to operate as a public company until the close, with existing trading rules and vesting schedules remaining in effect.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this announcement positively for Enhabit shareholders, offering a clear cash exit at a specified price, and for the company's future, promising additional resources and stability under private ownership.

Positives

• Enhabit will benefit from additional resources and expertise under Kinderhook's ownership, allowing for greater investment in the workforce, clinical capabilities, and supporting tools.
• Kinderhook is committed to fostering continuity for employees regarding benefits and compensation programs.
• No material changes are anticipated for day-to-day operations, team structure, or patient service.
• The acquisition provides a clear cash value of $13.80 per share for stockholders.

Negatives

• Enhabit will cease to be a standalone public company upon the transaction's close, removing its shares from public trading.

Risks

• The proposed transaction may not be completed in a timely manner or at all, which could adversely affect Enhabit's business and the price of its common stock.
• Failure to satisfy any of the conditions to the consummation of the transaction, including the receipt of certain regulatory approvals.
• Failure to obtain stockholder approval of the proposed transaction.
• The occurrence of any fact, event, change, development, or circumstance that could give rise to the termination of the transaction agreement, including in circumstances requiring Enhabit to pay a termination fee.
• The effect of the announcement or pendency of the proposed transaction on Enhabit's business relationships, operating results, and business generally.
• Risks that the proposed transaction disrupts Enhabit's current plans and operations.
• Enhabit's ability to retain and hire key personnel and maintain relationships with key business partners and customers in light of the proposed transaction.
• Diversion of management's attention from Enhabit's ongoing business operations.
• Unexpected costs, charges, or expenses resulting from the proposed transaction.
• The ability of Anchor Parent, LLC (Kinderhook) to obtain financing for the proposed transaction.
• Potential litigation relating to the proposed transaction that could be instituted against the parties or their respective directors, managers, or officers.
• Continued availability of capital and financing.
• Certain restrictions during the pendency of the proposed transaction that may impact Enhabit's ability to pursue certain business opportunities or strategic transactions.
• Other risks described in Enhabit's filings with the SEC, including its Annual Report on Form 10-K filed on March 6, 2025.

Future Outlook

Enhabit expects to continue providing high-quality home health and hospice services, benefiting from Kinderhook's additional resources and expertise to invest for the long term in its workforce, clinical capabilities, and tools. Day-to-day operations, team structures, strategy, and mission are anticipated to remain unchanged.

Management Comments

• "A press release was issued moments ago announcing that Enhabit has entered into an agreement to be acquired by Kinderhook Industries, a leading middle-market private equity firm." Barb Jacobsmeyer, President and CEO.
• "While this partnership will mean a change of ownership of Enhabit, our day-to-day operations, team structures, strategy and mission are expected to remain unchanged."
• "Under Kinderhook's ownership, Enhabit will benefit from additional resources and expertise that will allow us to reach even greater heights and give us additional flexibility to invest for the long term in our workforce, our clinical capabilities and the tools and resources that support your work."
• "Kinderhook has been clear that they are excited to partner with Enhabit because of our talented team members."
• "We are confident this is a terrific outcome for Enhabit and as a result of the transaction we expect to be even better able to meet their needs." (referring to patients)

Industry Context

StockSavvy.ai notes that the acquisition of Enhabit by a private equity firm like Kinderhook Industries reflects a broader trend in the healthcare sector, particularly in home health and hospice services, where private equity sees opportunities for operational efficiencies, market consolidation, and long-term growth through strategic investments. This move allows Enhabit to potentially accelerate its growth and investment strategies outside the pressures of public market quarterly reporting.

Comparison to Industry Standards

• The filing does not provide specific financial metrics or operational results to compare against industry benchmarks or specific competitors.
• StockSavvy.ai observes that private equity acquisitions in the home health and hospice sector are common, with firms like Blackstone, KKR, and Carlyle Group having invested in similar companies, often aiming to leverage scale and technology for improved patient outcomes and cost management.

Legal Proceedings

• Potential litigation relating to the proposed transaction could be instituted against the parties to the transaction agreement or their respective directors, managers, or officers.

Stakeholder Impact

• Shareholders: Will receive $13.80 in cash per share, including for unvested equity, upon the closing of the transaction.
• Employees: Day-to-day operations, team structures, strategy, mission, and overall compensation and benefits programs are expected to remain largely unchanged. Kinderhook is committed to investing in the workforce.
• Patients/Communities: The company expects to continue providing high-quality home health and hospice services, potentially enhanced by additional resources and expertise under new ownership.

Next Steps

• An all-employee email will be delivered shortly.
• A leaders-only call will be held later this morning (February 23, 2026) to provide additional context and guidance.
• Enhabit expects to announce a special meeting of stockholders as soon as practicable to obtain stockholder approval of the proposed transaction.
• Enhabit intends to file relevant materials with the SEC, including a proxy statement in preliminary and definitive form.
• The transaction is expected to close in the second quarter of 2026, subject to the receipt of stockholder and regulatory approvals, and the satisfaction of other customary closing conditions.
• More information with respect to employee benefits and compensation details will be communicated as they are finalized.
• Details on outstanding unvested equity will be provided when the transaction closes.

Key Dates

Recommendation

For current shareholders, a 'hold' recommendation is appropriate as the acquisition price of $13.80 per share is fixed, and the transaction is expected to close in Q2 2026. There is limited upside potential beyond the agreed-upon price, and holding until close allows for the realization of this value. For non-shareholders, there is no clear entry point for significant gains given the fixed acquisition price.

Keywords

Enhabit, Kinderhook Industries, acquisition, private equity, home health, hospice, merger, healthcare, SEC filing, DEFA14A, stock, shares, cash offer